Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Challenges to therapy in the future.

C O'Morain1, S Montague

  • 1Gastroenterology Department, Adelaide and Meath Hospital, Tallaght, Dublin, Ireland.

Helicobacter
|June 1, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Effectiveness of empirical <i>Helicobacter pylori</i> eradication therapy with furazolidone in Russia: results from the European Registry on <i>Helicobacter pylori</i> Management (Hp-EuReg)].

Terapevticheskii arkhiv·2023
Same author

[European Registry on the management of Helicobacter pylori infection: features of diagnosis and treatment in Kazan].

Terapevticheskii arkhiv·2020
Same author

[European registry Helicobacter pylori (Hp-EuReg): how has clinical practice changed in Russia from 2013 to 2018 years].

Terapevticheskii arkhiv·2020
Same author

European Registry on the management of Helicobacter pylori infection (Hp-EuReg): analysis of 2360 patients receiving first-line therapy in Russia.

Terapevticheskii arkhiv·2019
Same author

HBsAg and HBcrAg as predictors of HBeAg seroconversion in HBeAg-positive patients treated with nucleos(t)ide analogues.

Journal of viral hepatitis·2018
Same author

The association between Helicobacter pylori infection and inflammatory bowel disease based on meta-analysis.

United European gastroenterology journal·2015
Same journal

Active Helicobacter pylori Infection and Survival Outcomes in De Novo Metastatic Colorectal Cancer: A Retrospective Cohort Study.

Helicobacter·2026
Same journal

Current Status of Diagnosis, Treatment, and Prevention of Helicobacter pylori Infection in China: A 2024-2025 National Multicenter Cross-Sectional Study.

Helicobacter·2026
Same journal

Worldwide Phylogenetic and Clinical Risk Association of the Helicobacter pylori Outer Membrane Gene hopQ.

Helicobacter·2026
Same journal

Global Diversity of Helicobacter pylori Prophages Reveals Genetic Drivers of Virulence and Associations With Gastric Cancer.

Helicobacter·2026
Same journal

How to Improve Patient Adherence During Helicobacter pylori Diagnosis and Treatment.

Helicobacter·2026
Same journal

Efficacy and Safety of Tegoprazan-Based Dual, Triple, and Quadruple Therapies in First-Line Helicobacter pylori Eradication: A Prospective Randomized Controlled Trial.

Helicobacter·2026
See all related articles

Quadruple therapy effectively treats Helicobacter pylori, even with metronidazole resistance, by targeting genetic mechanisms. Future solutions include novel antibiotics and vaccines to combat increasing antimicrobial resistance.

Area of Science:

  • Microbiology
  • Pharmacology
  • Genetics

Background:

  • Antimicrobial resistance is a growing concern in Helicobacter pylori eradication.
  • Metronidazole resistance varies significantly by region, with genetic mutations in the rdxA gene implicated.
  • Macrolide and amoxicillin resistance are emerging issues affecting treatment efficacy.

Purpose of the Study:

  • To review current and future strategies for Helicobacter pylori eradication.
  • To address the challenges posed by antimicrobial resistance.
  • To explore novel therapeutic approaches and the development of a vaccine.

Main Methods:

  • Review of existing literature on Helicobacter pylori eradication therapies.
  • Analysis of genetic mechanisms underlying antimicrobial resistance.

Related Experiment Videos

  • Evaluation of alternative treatment regimens and novel drug development.

    • Main Results:

    • Quadruple therapy shows efficacy against metronidazole-resistant strains.
    • Alternative therapies, such as mucosal protective agents and octreotide, demonstrate potential.
    • Current triple therapy is highly effective in susceptible strains, but compliance is crucial.

    Conclusions:

    • Combating antimicrobial resistance requires understanding genetic targets and developing new drugs and vaccines.
    • Physician and patient education on compliance is vital to maintain treatment efficacy.
    • Future research should focus on personalized medicine and novel approaches for refractory infections.